What sets us apart
A new production paradigm for high-impact biopharmaceuticals in animal health.
Democratizing access to cutting-edge biopharmaceuticals
Fortgen Biologics was founded to solve one of the biggest challenges in the biopharmaceutical industry: producing high–biological-value biopharmaceuticals for price-sensitive segments, such as animal health and the biosimilars market.
While traditional production platforms—such as mammalian cell–based systems—require very high investments, Fortgen Biologics offers a radically more efficient model, combining complementary technologies that reduce costs without compromising quality, safety, or therapeutic performance.
Our goal is to make biologics for animal health economically viable, driving a new era of accessible and sustainable innovation.
Key differentiators
Fortgen’s core strength lies in the mastery
and integrated use of two synergistic platforms.
- Phage display: for the discovery and selection of high-affinity, high-specificity monoclonal antibodies;
- Animal Platform: for recombinant production in milk, with unmatched scalability and cost efficiency
This exclusive combination enables us to deliver biopharmaceuticals for animal health with tangible benefits across the entire value chain.
What we deliver
Efficacy and specificity
High-affinity biopharmaceuticals targeting specific therapeutic targets, developed using advanced selection technologies.
Biological safety
Production in the mammary gland results in favorable glycosylation profiles and greater molecular stability.
Patentable innovation.
Each developed molecule can generate strong intellectual property and robust commercial protection.
Flexible and sustainable scalability.
Upstream units can be easily replicated across different locations with low infrastructure costs.
A drastic reduction in operating costs.
Lower capital tied up, reduced production costs, and a lower barrier to entry for new products.
Industrial simplicity and reproducibility.
Consistent processes that are easy to replicate and support regulatory compliance.
Efficacy and specificity
High-affinity biopharmaceuticals targeting specific therapeutic targets, developed using advanced selection technologies.
Biological safety
Production in the mammary gland results in favorable glycosylation profiles and greater molecular stability.
Patentable innovation.
Each developed molecule can generate strong intellectual property and robust commercial protection.
Flexible and sustainable scalability.
Upstream units can be easily replicated across different locations with low infrastructure costs.
A drastic reduction in operating costs.
Lower capital tied up, reduced production costs, and a lower barrier to entry for new products.
Industrial simplicity and reproducibility.
Consistent processes that are easy to replicate and support regulatory compliance.
Drug Development Pipeline.
Fortgen Biologics is advancing the development of monoclonal antibodies aimed at treating chronic and oncological diseases in companion animals.
Our pipeline prioritizes innovative therapies with strong market potential and proven efficacy, combining our expertise in Phage Display and Animal Platform technologies.
Creating value for partners and investors.
Fortgen Biologics is positioned to be a strategic player in veterinary biotechnology, offering a platform that combines technological efficiency, sustainability, and economic potential.
Our production model has the power to transform the relationship between innovation and accessibility, creating opportunities for partnerships, co-development, and licensing in a rapidly expanding global market.
With cutting-edge technologies and full control of the production process, Fortgen develops biopharmaceuticals for animal health — with quality comparable to human medicine, but at costs aligned with the realities of veterinary care.
Fortgen Biologics — efficient, scalable, and accessible biotechnology to transform the future of biopharmaceuticals in animal health.
Get in touch and discover how we can create value together.